David Hoffman

3.1k total citations
62 papers, 2.0k citations indexed

About

David Hoffman is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, David Hoffman has authored 62 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Endocrinology, Diabetes and Metabolism, 19 papers in Oncology and 14 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in David Hoffman's work include Growth Hormone and Insulin-like Growth Factors (20 papers), Diet and metabolism studies (10 papers) and Lipid metabolism and disorders (10 papers). David Hoffman is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (20 papers), Diet and metabolism studies (10 papers) and Lipid metabolism and disorders (10 papers). David Hoffman collaborates with scholars based in United States, Australia and United Kingdom. David Hoffman's co-authors include Ken K. Y. Ho, Anthony O’Sullivan, Robert Baxter, J. Freund, K C Leung, Anne T. Reutens, Mark W. Duncan, John J. Kelly, Robert A. Figlin and A. Margot Umpleby and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

David Hoffman

62 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Hoffman United States	23	1.3k	427	425	335	285	62	2.0k
Maki Urushihara Japan	29	699 0.5×	196 0.5×	590 1.4×	1.0k 3.0×	134 0.5×	81	2.5k
Pascale H. Lane United States	23	417 0.3×	201 0.5×	364 0.9×	317 0.9×	322 1.1×	53	1.8k
Elisabeth Widén Finland	22	740 0.6×	526 1.2×	922 2.2×	240 0.7×	543 1.9×	29	2.5k
Michiaki Abe Japan	20	336 0.3×	160 0.4×	310 0.7×	182 0.5×	126 0.4×	82	1.8k
Axel Muendlein Austria	24	251 0.2×	295 0.7×	615 1.4×	299 0.9×	227 0.8×	124	1.7k
Michal Herman‐Edelstein Israel	19	570 0.4×	271 0.6×	1.1k 2.6×	222 0.7×	135 0.5×	33	2.9k
H.J.M. van Rijn Netherlands	22	272 0.2×	284 0.7×	349 0.8×	287 0.9×	73 0.3×	59	1.5k
Bengt Hallengren Sweden	26	1.1k 0.9×	207 0.5×	178 0.4×	65 0.2×	296 1.0×	64	1.8k
Tracy E. Hunley United States	23	328 0.2×	217 0.5×	455 1.1×	446 1.3×	88 0.3×	45	1.7k
Susanna Boquist Sweden	20	496 0.4×	266 0.6×	322 0.8×	460 1.4×	132 0.5×	26	1.6k

Countries citing papers authored by David Hoffman

Since Specialization

Citations

This map shows the geographic impact of David Hoffman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Hoffman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Hoffman more than expected).

Fields of papers citing papers by David Hoffman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Hoffman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Hoffman. The network helps show where David Hoffman may publish in the future.

Co-authorship network of co-authors of David Hoffman

This figure shows the co-authorship network connecting the top 25 collaborators of David Hoffman. A scholar is included among the top collaborators of David Hoffman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Hoffman. David Hoffman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patel, Maulik, Jalaja Potluri, Thomas Marbury, et al.. (2025). Pharmacokinetics and Safety of Navitoclax in Hepatic Impairment. Clinical Pharmacokinetics. 64(4). 611–617. 1 indexed citations

Garcia, Jacqueline S., Uwe Platzbecker, Olatoyosi Odenike, et al.. (2024). Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood. 145(11). 1126–1135. 7 indexed citations

Horinouchi, Hidehito, Jonathan W. Goldman, Byoung Chul Cho, et al.. (2023). O7-4 Phase 1b efficacy of telisotuzumab vedotin and osimertinib in Asian vs non-Asian patients with advanced NSCLC. Annals of Oncology. 34. S1387–S1387. 1 indexed citations

Garcia‐Manero, Guillermo, Olatoyosi Odenike, Shaun Fleming, et al.. (2023). Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation. Blood. 142(Supplement 1). 1868–1868. 3 indexed citations

Hoffman, David, Nils Boehm, Bruno C. Medeiros, et al.. (2023). Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study. Cancer Chemotherapy and Pharmacology. 93(4). 329–339. 1 indexed citations

Badawi, Mohamed, Xin Chen, Patrick Marroum, et al.. (2022). Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet. Clinical Drug Investigation. 42(8). 657–668. 6 indexed citations

Zeidan, Amer M., Uma Borate, Daniel A. Pollyea, et al.. (2021). Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome. Blood. 138(Supplement 1). 537–537. 13 indexed citations

Place, Andrew E., Kelly C. Goldsmith, Jean‐Pierre Bourquin, et al.. (2018). Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies. Future Oncology. 14(21). 2115–2129. 39 indexed citations

Marroum, Patrick, Silpa Nuthalapati, Apurvasena Parikh, et al.. (2018). Industry Perspective on Standardizing Food-Effect Studies for New Drug Development. Clinical Pharmacokinetics. 57(8). 901–909. 2 indexed citations

10.

Freise, Kevin J., et al.. (2016). Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure–response analysis. Cancer Chemotherapy and Pharmacology. 78(4). 847–853. 25 indexed citations

11.

Lam, Teresa, David Hoffman, Kimberly Cukier, et al.. (2016). Temporal HbA1c patterns amongst patients with type 2 diabetes referred for specialist care: Data from the S4S-DINGO-Diabetes Informatics Group. Diabetes Research and Clinical Practice. 116. 159–164. 2 indexed citations

12.

Camidge, D. Ross, Eamon M. Berge, Robert C. Doebele, et al.. (2014). A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 9(10). 1532–1539. 41 indexed citations

13.

Hoffman, David. (2013). Circadian Variation and Baseline Definition in Parallel-Group Thorough QT Studies. Therapeutic Innovation & Regulatory Science. 48(2). 272–286. 2 indexed citations

14.

Boudville, Neil, Anna Kemp, Robert G. Fassett, et al.. (2012). Factors Associated with Chronic Kidney Disease Progression in Australian Nephrology Practices. Nephron Clinical Practice. 121(1-2). c36–c41. 3 indexed citations

15.

Harpur, Ernie, Daniela Ennulat, David Hoffman, et al.. (2011). Biological Qualification of Biomarkers of Chemical-Induced Renal Toxicity in Two Strains of Male Rat. Toxicological Sciences. 122(2). 235–252. 94 indexed citations

16.

Burt, Morton G., James Gibney, David Hoffman, A. Margot Umpleby, & Ken K. Y. Ho. (2007). Relationship between GH-induced metabolic changes and changes in body composition: A dose and time course study in GH-deficient adults. Growth Hormone & IGF Research. 18(1). 55–64. 22 indexed citations

17.

Wolthers, Troels, David Hoffman, A. G. Nugent, et al.. (2001). Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. American Journal of Physiology-Endocrinology and Metabolism. 281(6). E1191–E1196. 96 indexed citations

18.

Hoffman, David & Robert A. Figlin. (2000). Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World Journal of Urology. 18(2). 152–156. 27 indexed citations

19.

Ho, Ken K. Y. & David Hoffman. (1995). Defining growth hormone deficiency in adults. Metabolism. 44(10 Suppl 4). 91–96. 22 indexed citations

20.

Hoffman, David, et al.. (1994). Agranulocytosis and hepatic dysfunction following propylthiouracil treatment. Australian and New Zealand Journal of Medicine. 24(4). 409–410. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact